A trial of recombinant alpha 2 interferon in the XXXX : I. Clinical results.

@entity1 @entity7139 @entity417 @entity6130 @entity2590 @entity3052 @entity491
Interferon has been reported to have differentiation promoting effects in certain model systems. Because of this and other potentially beneficial effects, a trial of recombinant alpha 2 interferon was undertaken in @entity2590 . The study population consisted of 14 @entity1 , subclassified as two @entity417 ( @entity417 ), one @entity417 ( @entity417 ), nine @entity7139 ( @entity7139 ), and two @entity6130 ( @entity6130 ). The planned dosage schedule was 2.0 MU/M2 t.i.w. sc x 2 weeks q 4 weeks for at least two cycles. No @entity1 achieved the prospective remission criteria, which included sustained blood count improvements. Transient improvements of platelet counts of greater than 50% in baseline were noted in six @entity1 , and a transient antileukemic effect was noted in one @entity1 with @entity6130 . @entity2590 @entity1 were found to be sensitive to the count suppressing effects of alpha 2 interferon with greater than 25% suppression of granulocytes, platelets, or reticulocytes transiently noted in 11 @entity1 and decreasing bone marrow cellularity noted in two while on treatment. Because of these effects, dosage adjustments were frequently instituted in the @entity417 , @entity417 , and @entity7139 @entity1 . The average dosages and durations of treatment received were thus 1.48 MU/M2 x 19.4 injections for @entity1 with @entity417 , @entity417 , and @entity7139 and 2.25 MU/M2 x 27 injections for the @entity6130 @entity1 . Progression to @entity3052 or @entity7139 in transformation was noted in five @entity1 , and increasing @entity491 was noted in one @entity6130 @entity1 while on protocol. It cannot be determined at this time whether these transformations were accelerated by alpha 2 interferon or represent selection bias in this study population. Although some evidence of beneficial effects was noted, alpha 2 interferon in this dosage and schedule is not a useful treatment for @entity2590 .
